热门资讯> 正文
Nuvation Bio将发行2亿美元可转换优先票据
2026-06-25 19:12
- Nuvation Bio (NUVB) plans to offer $200M aggregate principal amount of convertible senior notes due in 2032 in an underwritten offering.
- The firm also intends to grant the underwriters a right to purchase up to an additional $30M of the notes, solely to cover over-allotments, if any.
- The notes will mature on July 1, 2032, unless earlier converted, redeemed, or repurchased.
- The interest rate, initial conversion rate, and other terms will be determined at the time of pricing.
- Nuvation Bio expects to use the net proceeds from the offering to pay the cost of the capped call transactions, repay in full all obligations under its senior secured loan agreement, and for general corporate purposes.
- NUVB shares fell -12% premarket to $5.66.
More on Nuvation Bio
- Nuvation Bio: David Hung's Latest Venture Looks Undervalued At Current Level
- Nuvation Bio: Buy The Ibtrozi Launch (Rating Upgrade)
- Nuvation Bio Inc. (NUVB) Presents at Jefferies Global Healthcare Conference 2026 Transcript
- Nuvation bid to expand Ibtrozi label undergoes FDA review
- Nuvation Bio expects gross-to-net to stabilize around 30% as IBTROZI shifts to >50% TKI-naive starts
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。